ticagrelor

ACC 2020 Virtual | PRONOMOS: Rivaroxaban superior a la enoxaparina en cirugías ortopédicas

Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb. After an orthopedic<a href="https://solaci.org/en/2020/04/06/virtual-acc-2020-pronomos-rivaroxaban-superior-to-enoxaparin-in-orthopedic-surgery/" title="Read more" >...</a>

ACC 2020 Virtual | TAILOR PCI: indicar clopidogrel en base a los genes no cambia la historia

Virtual ACC 2020 | TAILOR-PCI: Gene-Based Prescribing of Clopidogrel Does Not Change Outcomes

This very interesting work leaves us with a sour taste in our mouth, as it failed to meet its primary endpoint. Using genotype to individualize treatment with a P2Y12 inhibitor in patients with acute coronary syndrome or stable patients after a scheduled angioplasty compared with conventional treatment with clopidogrel does not reduce the risk of<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-tailor-pci-gene-based-prescribing-of-clopidogrel-does-not-change-outcomes/" title="Read more" >...</a>

mas-leido-febrero-eng-420x283-compressor

The Most Read Scientific Articles of February

01- Alternatives for Patients Allergic to Aspirin The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a recommendation to use monotherapy with the most potent antiaggregant we<a href="https://solaci.org/en/2020/03/11/the-most-read-scientific-articles-of-february/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Alternatives for Patients Allergic to Aspirin

Intolerance to aspirin is relatively frequent and there is no other non-steroid anti-inflammatory medication to replace it. The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a<a href="https://solaci.org/en/2020/03/02/alternatives-for-patients-allergic-to-aspirin/" title="Read more" >...</a>

The Most Read Scientific Articles of January in Solaci.org

The Most Read Scientific Articles of January in Solaci.org

01- Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence? There is no such thing as coincidence, at least not for the evidence-based medical science. This is what the NOBLE 5-year outcomes, soon to be published in the Lancet, seem to say, in line with the BBC exposé of the EXCEL<a href="https://solaci.org/en/2020/02/05/the-most-read-scientific-articles-of-january-in-solaci-org/" title="Read more" >...</a>

ticagrelor diabeticos

The Elderly and Polypharmacy: What to Discontinue

We often receive elderly poly-medicated patients (with more than 10 different drugs) who ask us to reassess these prescriptions and, if possible, discontinue some drugs. The reasons are many: they forget to take it, mix up intakes or drugs, and of course, most often find it expensive.&nbsp; Statins are one of the most expensive drugs<a href="https://solaci.org/en/2020/01/10/the-elderly-and-polypharmacy-what-to-discontinue/" title="Read more" >...</a>

AHA 2019 | TWILIGHT: discontinuar la aspirina luego de un síndrome coronario agudo

AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome

This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS).  In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the<a href="https://solaci.org/en/2019/11/20/aha-2019-twilight-discontinue-aspirin-after-acute-coronary-syndrome/" title="Read more" >...</a>

¿La elevación de marcadores luego de una angioplastia electiva no debería preocuparnos?

Should Post-PCI Biomarkers Elevation Be of Concern?

Elevated markers after PCI in stable patients treated with the latest generation stents continues to happen. However, only the association between biomarker elevation with creatine kinase-myocardial band (CK-MB) should be of concern, sin it was associated with mortality at one year. Post procedural cardiac troponin (cTn) elevation was not associated to future events, according to<a href="https://solaci.org/en/2019/11/11/should-post-pci-biomarkers-elevation-be-of-concern/" title="Read more" >...</a>

Lo Más Leído de Septiembre en Solaci.org

The Most Read Scientific Articles in September at Solaci.org

1- ESC 2019 | New European Guidelines on “Chronic Coronary Syndromes” In Paris, during the European Society of Cardiology (ESC) Congress 2019 Scientific Sessions, new guidelines for the diagnosis and treatment of chronic coronary syndromes were presented. This document, simultaneously published in Euro Heart J, updates the 2013 guidelines on stable ischemic heart disease and<a href="https://solaci.org/en/2019/10/21/the-most-read-scientific-articles-in-september-at-solaci-org/" title="Read more" >...</a>

Highlights TCT 2019

TCT 2019 | Onyx ONE: Durable Polymer vs. Polymer-Free Stent with Only One Month of Dual Antiplatelet Therapy

Courtesy of the SBHCI. This is the first randomized study comparing a durable-polymer drug-eluting stent (zotarolimus-eluting stent Onyx) and a polymer-free drug-eluting stent (biolimus-A9-coated stent BioFreedom), with only one month of dual antiplatelet therapy in patients at high risk for bleeding. Onyx ONE was a study conducted at 84&nbsp;sites that randomized 1:1 2000&nbsp;total patients at<a href="https://solaci.org/en/2019/09/30/tct-2019-onyx-one-durable-polymer-vs-polymer-free-stent-with-only-one-month-of-dual-antiplatelet-therapy/" title="Read more" >...</a>

Top